Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
IRWD 
Ironwood Pharmaceuticals Inc (IRWD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: IRWD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $0.95
1 Year Target Price $0.95
| 0 | Strong Buy |
| 0 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -70.96% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 118.27M USD | Price to earnings Ratio - | 1Y Target Price 0.95 |
Price to earnings Ratio - | 1Y Target Price 0.95 | ||
Volume (30-day avg) 4 | Beta 0.23 | 52 Weeks Range 0.53 - 7.11 | Updated Date 06/30/2025 |
52 Weeks Range 0.53 - 7.11 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.19 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -10.18% | Operating Margin (TTM) -25.64% |
Management Effectiveness
Return on Assets (TTM) 12.03% | Return on Equity (TTM) -574.72% |
Valuation
Trailing PE - | Forward PE 12.33 | Enterprise Value 607369202 | Price to Sales(TTM) 0.37 |
Enterprise Value 607369202 | Price to Sales(TTM) 0.37 | ||
Enterprise Value to Revenue 1.91 | Enterprise Value to EBITDA 10.11 | Shares Outstanding 161820000 | Shares Floating 117960196 |
Shares Outstanding 161820000 | Shares Floating 117960196 | ||
Percent Insiders 2.68 | Percent Institutions 97.45 |
Analyst Ratings
Rating 2 | Target Price 0.95 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 4 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Ironwood Pharmaceuticals Inc
Company Overview
History and Background
Ironwood Pharmaceuticals, Inc. was founded in 1998. It is a gastrointestinal (GI) healthcare company, focusing on developing and commercializing novel medicines to treat GI diseases. Significant milestones include the FDA approval and commercialization of LINZESSu00ae/CONSTELLAu00ae.
Core Business Areas
- Linzess Commercialization: Commercialization of LINZESS/CONSTELLA, a prescription medicine approved for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). This includes marketing, sales, and distribution activities.
- Research and Development: Discovery and development of new GI therapies. This encompasses preclinical and clinical research activities, including drug formulation and clinical trials.
- Partnerships and Licensing: Collaboration with other pharmaceutical companies through licensing agreements. This includes generating revenue from royalties and licensing fees.
Leadership and Structure
Tom McCourt is the CEO. The company has a board of directors overseeing management. The organizational structure is functionally based, with departments for commercial operations, R&D, finance, and legal.
Top Products and Market Share
Key Offerings
- Linzess/Constella (linaclotide): Linzess is used for the treatment of IBS-C and CIC. Market share fluctuates but is a leading prescription medication in its class. Competitors include Trulance (plecanatide) from Synergy Pharmaceuticals (acquired by Bausch Health) and Amitiza (lubiprostone) from Sucampo Pharmaceuticals (acquired by Mallinckrodt).
Market Dynamics
Industry Overview
The gastrointestinal therapeutics market is large and growing, driven by increasing prevalence of GI disorders and demand for new treatments. The market is characterized by competition among established pharmaceutical companies and emerging biotech firms.
Positioning
Ironwood is a mid-sized pharmaceutical company focused on GI diseases. Its competitive advantage lies in its expertise in GI therapeutics and its established commercial infrastructure for LINZESS/CONSTELLA.
Total Addressable Market (TAM)
The global constipation market is estimated to be $9.1 billion in 2024 and projected to reach $12.0 Billion by 2032. Ironwood is positioned to capture a significant portion of this market through Linzess/Constella and potential future GI therapies.
Upturn SWOT Analysis
Strengths
- Established commercial infrastructure for LINZESS/CONSTELLA
- Deep expertise in GI therapeutics
- Strong partnership with AbbVie for LINZESS in the US
- Pipeline of novel GI therapies
Weaknesses
- High dependence on LINZESS/CONSTELLA sales
- Competition from other GI therapies
- Limited product diversification
- Regulatory and reimbursement risks
Opportunities
- Expansion of LINZESS/CONSTELLA indications
- Development and commercialization of new GI therapies
- Strategic acquisitions or partnerships
- Geographic expansion
Threats
- Generic competition for LINZESS/CONSTELLA
- Clinical trial failures
- Changes in healthcare regulations and reimbursement policies
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- BHC
- MNK
- ACHC
Competitive Landscape
Ironwood faces competition from other pharmaceutical companies with GI products. Its success depends on its ability to differentiate LINZESS/CONSTELLA and develop innovative new therapies.
Major Acquisitions
VectivBio Holding AG
- Year: 2023
- Acquisition Price (USD millions): 1000
- Strategic Rationale: Expansion into rare gastrointestinal diseases and adds potential block buster medication to pipeline.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been dependent on LINZESS/CONSTELLA sales. R&D initiatives drive longer-term trajectory.
Future Projections: Future growth relies on expanding the use of Linzess/Constella and the success of new therapeutics in its pipeline.
Recent Initiatives: Recent initiatives include advancing its GI pipeline programs and exploring strategic partnerships.
Summary
Ironwood Pharmaceuticals is a GI-focused company with LINZESS/CONSTELLA as its primary revenue driver. Its strengths lie in its expertise and established partnerships. Weaknesses include reliance on a single product. Opportunities include expanding indications and the threats include generic competition for their main drug.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Ironwood Pharmaceuticals Investor Relations
- SEC Filings (10-K, 10-Q)
- Market research reports on the GI therapeutics market
- Analyst reports
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market data is subject to change and may not be entirely accurate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ironwood Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2010-02-03 | CEO & Director Mr. Thomas A. McCourt | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 253 | Website https://ironwoodpharma.com |
Full time employees 253 | Website https://ironwoodpharma.com | ||
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.